US President Bill Clinton signed into law the Food and DrugAdministration Modernization Act of 1997 (details of which appeared in Marketletter November 24) at a White House ceremony on November 21. The legislation received widespread support and passed Congress on November 9 with overwhelming bipartisan backing.
At the ceremony, Mr Clinton said the FDA is the "gold standard" for protecting the public interest and that this legislation should be awarded a "gold medal." The legislation is important because it maintains and redefines public interest at a time when there are new challenges in food safety and when there are new possibilities in medicine and medical devices, the President said.
The new law lets the FDA continue working with the medical and business communities to get new drugs and devices approved far earlier than before, he noted, and it offers hope to many critically-ill Americans by extending access to drugs and devices whose approval is still pending. For many people, he added, experimental treatment represents the best and perhaps the only chance of recovery.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze